Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19

TARRYTOWN, N.Y., Aug. 19, 2020 /PRNewswire/ -- REGN-COV2 is Regeneron's two-antibody 'cocktail' currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection The companies will collaborate on developing and manufacturing REGN-COV2; Regeneron will...

from PR Newswire: https://ift.tt/3aB6kIl